Drugs / EF-022
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02854761 | Sep 2016 → Sep 2018 | recurrent respiratory papillomatosis | Efranat Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02052492 | May 2014 → May 2017 | cancer | Efranat Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EF-022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02854761 ↗ |
| Modality | Protein / enzyme biologic | “Efranat has developed cancer immunotherapy based on Macrophage Activating Factor produced from natural Gc protein extracted from FDA approved healthy human plasma.” NCT02052492 ↗ |
| Route | Intramuscular | “Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks” NCT02052492 ↗ |